60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Investing.com -- Oxford Instruments PLC (LON:OXIG) on Monday reported that its first-half revenue is expected to decline approximately 8% on an organic constant currency basis compared to the prior year, as tariff disruptions and global economic uncertainty weighed on performance.
The scientific technology provider’s shares fell 6% following the trading update.
The company experienced contrasting dynamics across its divisions, with first-half order intake growing just over 1% on an organic constant currency basis versus the prior year.
After a first-quarter decline of around 3%, orders improved with nearly 6% growth in the second quarter, resulting in a half-year book-to-bill ratio of approximately 1.1.
"The start of our financial year coincided with the beginning of a turbulent time in our markets, as others in the sector have commented on," said CEO Richard Tyson. "I am proud of our team’s proactive and customer-focused approach to this very dynamic global trading landscape, driving an improving picture in Q2, albeit we are now assuming that we will not recover the H1 revenue shortfall."
The Imaging & Analysis division was hit harder than anticipated, with order intake falling around 6% in the first half as academic and commercial customers delayed purchases in response to shifting global trade conditions. First-quarter orders dropped 11% before stabilizing in the second quarter.
In contrast, the Advanced Technologies division saw strong momentum in its compound semiconductor business, with 25% order growth in the first half, driven by augmented reality and datacomms applications. Despite this strength, divisional revenue is expected to be approximately 7% lower than the prior year due to tariff-related delays in shipments to China.
The company now expects full-year revenue, adjusted operating profit, and operating profit margin to be similar to the prior year on an organic constant currency basis. Oxford Instruments also noted that its planned sale of the NanoScience business is progressing well and expected to complete during the third quarter.